TABLE 3.
Time‐to‐event outcomes of patients in CAR‐T cell therapy clinical trials
| ZUMA‐1 4 (N = 101) | JULIET 2 , 10 , 11 (N = 115) | TRANSCEND 6 (N = 256) | |
|---|---|---|---|
| Median DOR, (95% CI) | NR (10.9‐NE) | NR (10.0‐NE) | NR (8.6‐NR) |
| DOR at month 12, % (95% CI) | – | 65 (49–78) | 54.7 (46.7–62.0) |
| DOR at month 24, % (95% CI) | – | – | 52.1 (43.6–49.8) |
| Median OS, months (95% CI) | NR (12.8‐NE) a | 11.1 (6.6–23.9) | 21.1 (13.3‐NR) |
| OS at month 12, % (95% CI) | 59 (49–68) 5 | 48.2 (38.6–57.1) | 57.9 (51.3–63.8) |
| OS at month 24, % (95% CI) | 50.5 (40.2–59.7) | 40.0 (30.7–49.1) | 44.9 (36.5–52.9) |
| Median PFS, months (95% CI) | 5.9 (3.3–15.0) a | NR | 6.8 (3.3–14.1) |
| PFS at month 12, % (95% CI) | 44 (34–53) 5 | – b | 44.1 (37.3–50.7) |
| PFS at month 24, % (95% CI) | – c | – | 42.1 (35.0–48.9) |
| Follow‐up, months | 27.1 | 32.6 | 12.0–17.5 d |
Note: The purpose of this table is to summarize data. Head‐to‐head studies have not been performed and no comparisons can be made.
Abbreviations: CAR, chimeric antigen receptor; DOR, duration of response; NE, not estimable; NR, not reached; OS, overall survival; PFS, progression‐free survival.
‐ refers to not reported or known values; CAR, chimeric antigen receptor.
Investigator assessed; all other data are based on assessment by independent review committee.
Among responders at 3 months the PFS at 12 months was 83% (95% CI, 74% to 96%).
Among responders at 3 months the PFS at 24 months was 72% (95% CI, 56%–83%).
Follow‐up 12.0 months for DOR, 12.3 months for PFS, and 17.5 months for OS.